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Background: Concurrent study of secretomic and glycoproteomic profiles in cancer cell lines represents an
excellent approach for investigating cancer progression and identifying novel biomarker candidates. In this study,
we performed a comparative secretomic and N-glycoprotein profiling from the secretions of normal human
mammary epithelial cells (HMEpC) and the MCF-7 human breast cancer cell line.
Method: We analyzed these cell lines using a combined methodology involving glycan-binding lectins and
two-dimensional electrophoresis and identified several differentially secreted factors, including osteonectin and
haptoglobin.
Result: Notably, comparative analyses also revealed that MCF-7 cells produced differentially N-glycosylated forms of
haptoglobin.
Conclusion: The present data suggested that osteonectin and haptoglobin might have potential to be served as
potential biomarkers for breast cancer. However, further investigation is needed to validate the findings.
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Breast cancer is one of the most common cancers affect-
ing women worldwide, accounting for almost 23% of all
cancers diagnosed in women [1,2]. Although the mortal-
ity rate has decreased by 26.58% from 1991 to 2005,
breast cancer remains as one of the leading causes of
death in women [3]. This is mainly due to late stage
diagnosis and lack of effective treatments. Therefore,
early detection is critical for successful therapy and ul-
timate survival of breast cancer patients.
Human breast cancer cell lines provide an excellent
tool for investigating tumor progression and therapy. In
fact, secretome profiling of cell lines could represent an
efficient method for discovering novel biomarkers for* Correspondence: chenyeng@um.edu.my
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unless otherwise stated.early breast cancer detection [4]. According to Lai et al.,
false positive results obtained from tumor specimens could
be minimized through the identification of potential diag-
nostic proteins that are secreted by cancer cells [5]. During
tumorigenesis, it is known that secreted proteins can dir-
ectly participate in cancer cell migration, invasion, growth
control, angiogenesis, matrix degradation, and adhesion
[6]. Therefore, analysis of these tumor-secreted factors not
only contributes to our knowledge of the molecular mech-
anisms involved in tumorigenesis and metastasis, but also
represents a promising strategy for identifying biomarkers.
Glycosylation is an enzymatic process that attaches
glycans to proteins, lipids, or other organic molecules.
Glycosylation functionally contributes to protein stability
as well as cell–cell recognition and communication [7].
For this reason, modifications in glycans can contribute
to tumorigenesis. Changes in glycans include lost or ex-
cessive expression of certain structures, incomplete/
truncated structures, accumulation of precursors, and/or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion patterns are associated with cancer invasiveness and
metastatic potential [9]. Most of the secreted proteins
are known to be N-glycosylated [10]. Therefore, com-
parative studies of N-glycosylation profiles of secreted
proteins in malignant cell lines and normal cell lines
could provide important clues related to tumor diagnosis
and prognosis.
In this study, we conducted a comparative analysis of
N-glycoprotein secretion from normal human mammary
epithelial cells (HMEpC) and the MCF-7 human breast
cancer cell line, which is of luminal epithelial origin and
used as a model for estrogen receptor-positive tumors. To
detect N-glycoproteins secreted from these cell lines we
utilized Concanavalin A (ConA) extracted from Conca-
navalia ensiformis, which selectively recognizes alpha-
mannose of N-glycan. Herein, we have coupled the use
of these glycan-binding lectins with two-dimensional
electrophoresis (2-DE) in order to identify proteins that




The human breast cancer cell line, MCF-7 (catalog num-
ber: HTB-22), and human mammary epithelial cell line,
HMEpC (catalog number: 830 K-05a), were purchased
from American Type Culture Collection (ATCC) and Cell
Applications, respectively.
Sampling of growth medium
Similar amount of MCF-7 and HMEpC cells line were cul-
tured in separate flasks with FBS-containing growth media
and human mammary epithelial cell growth medium, re-
spectively. The growth medias were removed when cells
were approximately 80% confluent (108 cells) in a 75 cm2
flask. The cells were then washed three times with phos-
phate buffered saline (PBS) and incubated for an additional
24 h in serum-free DMEM. Ten milliliter of serum-free
media was subsequently harvested, centrifuged at 2,000 × g
to remove debris, and stored at –80°C. Prior to 2D-E, the
samples were concentrated 100-fold using Vivaspin 10,000
molecular weight cut-off concentrators (Sartorius) and
desalted with 2-D Clean-Up Kits (GE Healthcare Bio-
Sciences, Uppsala, Sweden).
Two-dimensional electrophoresis (2D-E)
2D-E was performed as previously described [11]. Briefly,
proteins were rehydrated in 250 μl of rehydration buffer
(8 M urea, 2 M thiourea, 4% CHAPS, 0.5% pharmalyte,
20 mM dithiothreitol) overnight in 13 cm precast immobi-
lized dry strips at pH 4–7 (GE Healthcare Bio-Sciences).
The strips were then subjected to isoelectric focusing (IEF)
using the Ettan IPGphor 3 IEF System (GE Healthcare Bio-Sciences). They were subsequently equilibrated and sub-
jected to second dimensional separation at 16°C using so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) with 8–18% gradient gels. All samples were
analyzed in technically triplicate.
Silver staining
The 2D-E gels were silver stained as previously de-
scribed by Heukeshoven and Dernick [12]. For mass
spectrometric analysis, gels were silver stained as de-
scribed by Shevchenko et al. [13].
Concanavalin A chromatography
Ten milliliters of harvested medium was mixed with
2 ml of ConA Sepharose (GE Healthcare Bio-Sciences)
and rotated overnight at 4°C. The mixture was then loaded
into a column (0.8 cm × 4 cm) (Bio-Rad Laboratories,
Hercules, CA, USA) and equilibrated with equilibration
buffer (20 mM Tris-HCl, 0.5 M NaCl, pH 7.4). The col-
umn was washed with 50 ml of equilibration buffer to re-
move non-glycosylated and O-glycosylated proteins, and
bound N-glycoproteins were eluted with 0.3 M methyl-α-
D-glucopyranoside. Absorbance at 280 nm was measured
throughout the chromatographic process. Eluted fractions
were concentrated 100 times using Vivaspin concentrators
(10,000 molecular weight cut-off; Sartorius) and further
desalted with 2-D Clean-Up Kits (GE Healthcare Bio-
Sciences) and then subjected to 2-DE analysis.
Image analysis
Images of silver-stained 2D-E gels were captured using a
LabScan scanner (version 5; Amersham, Germany), and
PD-Quest™ 2D gel analysis software (version 8.0.1, Bio-
Rad) was used to detect, match, and quantify protein
spots. Normalization was achieved by dividing the raw
quantity of each spot in the gel by the total intensity of
pixels in the image in order to compensate for non-
expression related variations in protein spot intensities.
The variance ratio test (F) was used to analyse differ-
ences among the sample groups. A p-value less than
0.05 was considered statistically significant.
Mass spectrometric analysis and protein identification
Highly resolved spots of interest were excised and sub-
jected to in-gel tryptic digestion using ProteoExtract™ All-
in-One Trypsin Digestion Kit (Calbiochem, Darmstadt,
Germany). The trypsin-digested peptides were desalted
and concentrated using C18 Zip Tip Pipette Tips (Merck
Millipore, Billerica, MA, US). Mass spectrometric analysis
was performed at the Proteomic Centre, Department of
Biological Sciences, National University of Singapore. The
digested peptides were mixed with 1 μl of CHCA matrix
solution (5 mg/ml α-cyano-4-hydroxycinnamic acid in
0.1% trifluoroacetic acid and 50% acetonitrile in ultrapure
Tan et al. Cancer Cell International 2014, 14:120 Page 3 of 6
http://www.cancerci.com/content/14/1/120water) and spotted onto a matrix-assisted laser desorption/
ionization (MALDI) target plate. Mass spectra were
obtained using an ABI 4800 Proteomics Analyzer
MALDI-TOF/TOF Mass Spectrometer (Applied Biosys-
tems, Framingham, MA, USA). The five most intense ions
obtained from mass spectrometry (MS) were subsequently
subjected to MS/MS analysis using air with collision en-
ergy of 2 kV and a collision gas pressure of ~1×10-6 Torr.
Stop conditions specified 2,000–3,000 shots, depending
on the quality of the spectra. For protein identification,
mass spectra were compared with the National Center
for Biotechnology Information non-redundant (NCB









Figure 1 Typical 2-DE growth medium profiles. Panel A and panel B re
line, respectively. Acidic side of the gel is to the left and relative molecular
HMEpC cell line, but not in the growth media of MCF-7 cells.MASCOT search engine (version 2.1; Matrix Science,
London, UK). Searches were performed with fixed
modification on carbamidomethylation of cysteines
and variable modification of methionine oxidation.
The following parameters were used in the MASCOT
peptide mass fingerprint search: (i) enzyme: trypsin;
(ii) one missed cleavage allowed; (iii) mass value: mon-
oisotopic; (iv) peptide mass tolerance: ±0.1 Da; and (v)
peptide charge state: 1+. The same parameters were
used in the MASCOT ion search, except peptide mass
tolerance and fragment mass tolerance were set at
100 ppm and 0.2 Da, respectively. Search scores >50
indicated identity or extensive homology (p < 0.05).pI 10
pI 10
fer to typical 2-DE growth medium profiles of HMEpC and MCF-7 cell
mass declines from the top. ON was detected in the growth media of
Table 1 Mass spectrometric identification of protein spots from MCF-7 and HMEpC media using MASCOT search engine
and the NCBI database
Spot name Protein name MASCOT accession number Theoretical pI Theoretical mass (Da) No. of peaks matched Search score
HP Haptoglobin gi|223976 6.23 42,344 2 70
ON Osteonectin gi|338325 4.70 35,260 1 81
Tan et al. Cancer Cell International 2014, 14:120 Page 4 of 6
http://www.cancerci.com/content/14/1/120Results
Comparison of the MCF-7 and HMEpC growth media
profiles
Separation of MCF-7 media by 2D-E resulted in a high-
resolution protein profile, which was comprised of various
secreted factors (Figure 1B). However, we observed a con-
siderably low proteins profile when HMEpC media was an-
alyzed by 2D-E and silver staining. A protein cluster was
solely detected in HMEpC media but was absent in MCF-7
media. It was then identified as osteonectin (Figure 1A and
Table 1) when subjected to MS/MS analysis.Detection of N-glycoproteins using ConA chromatography
We next investigated changes in oligosaccharide moieties
on secreted proteins using a combined methodology,
which coupled Con A chromatography for enrichment of
N-glycoproteins based on alpha-mannose residues followed
by 2-DE analysis. Using these techniques, we analyzed
media harvested from MCF-7 and HMEpC cell lines and
observed differential N-glycoprotein profiles. Image ana-
lysis of ConA chromatography of MCF-7 media demon-
strated that the volumes of almost all matched spots were
comparable except haptoglobin glycoforms, which was de-
tected to be in low level compared to the total growth
media profile (Figure 2 and Table 1). The volumes of
other matched spots were comparable in both profiles.




Figure 2 Haptoglobin glycoforms. Panel A and panel B demonstrates th
2-DE total growth medium profile and N-glycoproteins profiles of MCF-7, rN-glycosylation profile of HMEpC media although it is
known to contain N-glycan (not shown) [14].
Discussion
Breast cancer cells acquire aberrant protein expression,
which can subsequently lead to alterations in post-
translational modifications. Glycosylation is a common
modification made to secreted proteins, which are in-
volved in a variety of physiological processes, such as
cancer cell signaling, matrix remodeling, and metastasis
[15]. Therefore, changes in glycosylation or glycan com-
position occurring during tumorigenesis can ultimately
contribute to cancer progression. In this study, we have
analyzed the secretory profile of the MCF-7 breast can-
cer cell line in order to identify aberrantly secreted and/
or glycosylated proteins.
Osteonectin (also known as secreted protein acidic
and rich in cysteine [SPARC]) is a secreted, phosphory-
lated, and calcium-binding glycoprotein that was first
isolated from bone [16]. It plays a role in regulating cell
adhesion, proliferation, migration, and tissue remodeling
[17]. Osteonectin overexpression was reported to be as-
sociated with malignancy in various tumors, including
breast, brain, and prostate carcinoma [18]. However,
there have also been reports of decreased osteonectin
expression being associated with tumorigenesis in hu-
man ovarian cancer [19] and poor prognosis in breast
cancer patients [20]. Thus, these studies have collectivelypI 6.5
e cropped image of β chain of haptoglobin glycoforms obtained from
espectively. It is a 45 kDa homotetramer with pI ranged from 5.5 to 6.5.
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ing tumorigenesis. We believe that these disparate find-
ings might relate to osteonectin isoforms, which could
be differentially expressed in various disease states. Our
findings indicated that osteonectin was secreted from
HMEpC, but not by MCF-7 cells. Osteonectin was not
detected in N-glycoprotein profiles of HMEpC, although
previous study has reported that it is a N-glycoprotein
[14]. Future studies will be needed to determine the func-
tional role and the N-glycosylation structure of osteonec-
tin in breast cancer .
Haptoglobin is a glycoprotein that is mainly produced
by hepatocytes. It binds to free hemoglobin to form
stable haptoglobin–hemoglobin complexes that help to
maintain iron ions in the blood. It also functions as an
acute-phase reactant, and a tumor variant of haptoglobin
exhibits immunosuppressor activity [21,22]. Structurally,
haptoglobin is a 90 kDa tetramer composed of two non-
identical α- and β-subunits linked by disulphide bonds
[23]. In this study, we only analyzed the β-subunits of
haptoglobin, which are glycosylated. Indeed, it was sur-
prising to observe haptoglobin secretion by MCF-7 cells
since it is a hepatocyte-secreted factor. Nevertheless, re-
cent studies have observed haptoglobin expression asso-
ciated with ovarian and breast tumors [21,22,24], as well
as ovarian and embryonic lung cancer cell lines [25].
Moreover, previous reports by Kuhajda et al. [24] and
Oh et al. [22] have indicated that the tumor variant of
haptoglobin displays aberrant structural changes that
may contribute to tumorigenesis. Since haptoglobin is a
secreted protein, its level should be equal to its glycosyl-
ated forms [26]. However, the present findings demon-
strated that β-haptoglobin glycoforms secreted by MCF-7
cells lacked N-glycosylation. This change in haptoglobin
N-glycosylation could affect extracellular matrix interac-
tions and/or contribute to immunosuppression of lympho-
cytes for promoting cancer. Therefore, we propose that the
tumor variant of haptoglobin undergoes both structural
and post-translational changes that are advantageous to
cancer cells during tumorigenesis.Conclusion
Our combined secretomic and glycoproteomic study of
the MCF-7 breast cancer cell line has yielded promis-
ing results. Comparative analyses have indicated that
differentially glycosylated forms of haptoglobin were
secreted by MCF-7 cells. This differentially secreted
factor may play a role in tumorigenesis and could rep-
resent useful biomarkers for future breast cancer re-
search and detection.Competing interest
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